High Growth Tech Stocks In South Korea For September 2024

The South Korea stock market has finished lower in three straight sessions, plunging more than 105 points or 4 percent along the way. The KOSPI now rests just above the 2,575-point plateau although it's due for support on Friday. Despite recent market volatility, identifying high growth tech stocks with strong fundamentals and innovative capabilities can offer substantial opportunities for investors looking to navigate these uncertain times.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	33.61%	52.05%	★★★★★★
IMLtd	21.80%	111.43%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
NEXON Games	29.64%	66.98%	★★★★★★
Park Systems	23.64%	35.66%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
UTI	114.97%	134.61%	★★★★★★

Click here to see the full list of 49 stocks from our KRX High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

PharmaResearch (KOSDAQ:A214450)

Simply Wall St Growth Rating: ★★★★★☆

Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea and has a market cap of ₩1.93 billion.

Operations: PharmaResearch Co., Ltd. generates its revenue primarily through its pharmaceuticals segment, which reported ₩296.59 billion in revenue. The company operates as a biopharmaceutical entity with a focus on South Korea.

PharmaResearch's earnings growth of 63.2% over the past year significantly outpaced the Biotechs industry average of 6.1%. With revenue forecasted to grow at 22.1% annually, it surpasses the broader KR market's expected growth rate of 10.3%. The company's commitment to innovation is evident from its substantial R&D expenditure, which has consistently driven advancements in their product pipeline. Additionally, PharmaResearch's projected earnings growth rate stands at an impressive 22.2% per year, highlighting its robust future prospects in South Korea’s high-growth tech landscape.

• Unlock comprehensive insights into our analysis of PharmaResearch stock in this health report.

• Evaluate PharmaResearch's historical performance by accessing our past performance report.

CJ CGV (KOSE:A079160)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CJ CGV Co., Ltd. operates theaters under the CJ CGV brand name in South Korea and has a market cap of ₩1.11 trillion.

Operations: CJ CGV Co., Ltd. generates revenue primarily through the operation of theaters in South Korea. The company's market cap stands at ₩1.11 trillion.

CJ CGV's recent earnings report shows a net loss of ₩3.70 billion for Q2 2024, significantly improving from the previous year's ₩44.08 billion loss. Despite the current unprofitability, revenue is forecasted to grow at 13.6% annually, surpassing South Korea's market average of 10.3%. The company's R&D expenses are pivotal; their investment in innovative technologies aims to enhance viewing experiences and operational efficiencies, with earnings projected to surge by 122% per year over the next three years.

• Get an in-depth perspective on CJ CGV's performance by reading our health report here.

• Examine CJ CGV's past performance report to understand how it has performed in the past.

Solum (KOSE:A248070)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Solum Co., Ltd. manufactures and markets power modules, digital tuners, and electronic shelf labels to customers in South Korea and internationally, with a market cap of ₩988.95 billion.

Operations: Solum Co., Ltd. generates revenue primarily from its ICT Business and Electronic Components Division, with the latter contributing ₩1.16 trillion. The company's market cap stands at ₩988.95 billion.

Solum's anticipated earnings growth of 37.2% annually over the next three years positions it robustly within South Korea's tech sector, outpacing the market average of 28.6%. The company's revenue is projected to increase by 14% per year, reflecting its strategic focus on innovation and expansion. With R&D expenses accounting for a significant part of their budget, Solum aims to enhance its technological capabilities and product offerings. A recent share repurchase program worth ₩20 billion underscores their commitment to shareholder value enhancement through stock price stabilization.

• Navigate through the intricacies of Solum with our comprehensive health report here.

• Gain insights into Solum's past trends and performance with our Past report.

Where To Now?

• Gain an insight into the universe of 49 KRX High Growth Tech and AI Stocks by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com